Legend Biotech ROE 2019-2022 | LEGN

Current and historical return on equity (ROE) values for Legend Biotech (LEGN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Legend Biotech ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $-0.35B $0.44B -94.04%
2021-12-31 $-0.39B $0.47B -124.54%
2021-09-30 $-0.36B $0.23B -135.36%
2021-06-30 $-0.30B $0.34B -102.67%
2021-03-31 $-0.34B $0.21B -111.62%
2020-12-31 $-0.30B $0.28B -143.06%
2020-09-30 $-0.31B $0.34B -277.40%
2020-06-30 $-0.27B $0.40B -967.86%
2020-03-31 $-0.17B $-0.17B 228.37%
2019-12-31 $-0.13B $-0.12B 432.52%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.483B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00